INTRODUCTION

Catridecacog (brand names Novothirteen, Tretten) is a recombinant Coagulation Factor XIII A-Subunit that is used to treat people with congenital deficiency or mutation of Factor XIII.

This plasmid is designed for expressing Catridecacog in yeast (Saccharomyces cerevisiae) expression system.

PRODUCT INFORMATION

Item No.: PPBD-42
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options for promoter and selection marker, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Catridecacog
Brand Names: Novothirteen, Tretten
Classification: Blood factors
Action type: Replacement therapy
Amino Acid Sequence: Identical to DB09310

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

Korte W. Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency? J Blood Med. 2014 Jul 9;5:107-13.

Contact Us